ALK 101
Alternative Names: ALK-101Latest Information Update: 31 Mar 2025
At a glance
- Originator Shanghai Allink Biotherapeutics
- Class Antineoplastics; Bispecific antibodies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Colorectal cancer; Non-small cell lung cancer; Solid tumours
Most Recent Events
- 28 Mar 2025 Preclinical trials in Colorectal cancer in China (unspecified route) (Shanghai Allink Biotherapeutics pipeline, March 2025)
- 28 Mar 2025 Preclinical trials in Non-small cell lung cancer in China (unspecified route) (Shanghai Allink Biotherapeutics pipeline, March 2025)
- 28 Mar 2025 Preclinical trials in Solid tumours in China (unspecified route) (Shanghai Allink Biotherapeutics pipeline, March 2025)